Home>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>KX2-391
KX2-391 Catalog No.GC14288

Src inhibitor,highly selective

Size Price Stock Qty
5mg
$50.00
In stock
10mg
$97.00
In stock
50mg
$294.00
In stock
250mg
$880.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1-3]:

Cell lines

HCC cell lines Huh7, PLC/PRF/5, Hep3B, and HepG2

Preparation method

The solubility of this compound in DMSO is >121mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

6,564 to 0.012 nM, 3 days

Applications

KX2-391 showed dose-response curves against all four HCC cell lines Huh7, PLC/PRF/5, Hep3B, and HepG2 with the GI50 of 9 nM, 13 nM, 26 nM, and 60 nM, respectively. In NIH3T3/c-Src527F and SYF/c-Src527F cells, KX2-391 inhibited cell growth with the GI50 of 23 nM and 39 nM, respectively. KXO1 (10-30 nM) could halve proliferation rates (GI50) of a panel of human cancer cell lines known to have activated levels of SFK- such as HT-29 human colon cancer cells, as well as NIH3T3/c-Src527F cells. KXO1 inhibited anchorage-independent growth of HT-29 and 3T3/c-Src527F cells.

Animal experiment [3]:

Animal models

nude mice bearing 50 cc HT-29 tumors

Dosage form

Oral administration, 5 mg/kg bid

Application

Treatment of nude mice bearing 50 cc HT-29 tumors with 5 mg/kg KXO1 bid p.o. resulted in a 70% reduction tumor growth, with no significant toxicity to the host as determined by weight loss.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Lau G M, Lau G M, Yu G L, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro[J]. Digestive diseases and sciences, 2009, 54(7): 1465-1474.

[2]. Fallah-Tafti A, Foroumadi A, Tiwari R, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities[J]. European journal of medicinal chemistry, 2011, 46(10): 4853-4858.

[3]. Bu Y, Gao L, Smolinski M, et al. KXO1 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo[J]. 2008.

Chemical Properties

Cas No. 897016-82-9 SDF
Chemical Name N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide
Canonical SMILES C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
Formula C26H29N3O3 M.Wt 431.53
Solubility ≥121mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

KX2-391 is a highly selective inhibitor of Src kinase with IC50 value of 20nM [1].

KX2-391 is a non-ATP competitive inhibitor of Src. It is the first inhibitor that targets Src kinase within the substrate binding site. KX2-391 inhibits Src catalyzed trans-phosphorylation of FAK, Shc, paxillin as well as Src kinase autophosphorylation. KX2-391 has no effects on PDGFR, EGFR, JAK1, JAK2 and Lck demonstrating it as a selective inhibitor. It is also found to be an inhibitor of tubulin polymerization through binding to the unique confirmation on heterodimeric tubulin. In cellular assays, KX2-391 shows growth inhibition in NIH3T3/c-Src527F cells and SYF/c-Src527F cells with GI50 values of 23nM and 39nM, respectively [1, 2].

Since Src acts as a regulator in cell proliferation survival, motility and invasiveness, KX2-391 is potent against a variety of solid tumors and many leukemia tumors. It is shown to inhibit primary tumor growth and to suppress metastasis [2].

References:
[1] Fallah-Tafti A, Foroumadi A, Tiwari R, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: Synthesis, Src kinase inhibitory and anticancer activities. European journal of medicinal chemistry, 2011, 46(10): 4853-4858.
[2] Naing A, Cohen R, Dy G K, et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket-directed SRC inhibitor, in patients with advanced malignancies. Investigational new drugs, 2013, 31(4): 967-973.